Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Xiaoying Chen; Cheryl Li; Reginald Ewesuedo; Donghua Yin

doi:10.1007/s00280-019-03890-7

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin^®) in patients with HER2‑positive metastatic breast cancer

Cancer Chemother Pharmacol. 2019 Sep;84(3):667. doi: 10.1007/s00280-019-03890-7.

Authors

Xiaoying Chen¹, Cheryl Li², Reginald Ewesuedo³, Donghua Yin⁴

Affiliations

¹ Early Oncology Development and Clinical Research, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 2121, USA. xiaoying.chen@pfizer.com.
² Clinical Pharmacology/Pharmacometrics, Pfizer Essential Health Research and Development, Pfizer Inc, 300 Technology Square, Cambridge, MA, 02140, USA.
³ Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA.
⁴ Early Oncology Development and Clinical Research, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 2121, USA.

Abstract

The article "Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin^®) in patients with HER2-positive metastatic breast cancer" written by Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin was originally published electronically on the publisher's internet portal (currently SpringerLink) on 3rd May 2019 without open access.

Publication types

Published Erratum